Maria Raquel da Costa Pinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Raquel da Costa Pinto has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Maria Fernanda Brandão Resende Guimarães
Federal University of Minas Gerais, Belo Horizonte, Brazil
3 shared publications Claiton Viegas Brenol
Affiliation Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
2 shared publicationsCleandro Pires de Albuquerque
Affiliation Universidade de Brasılia, Brasılia, Brazil
2 shared publications- Débora Cerqueira Calderaro
Federal University of Minas Gerais
2 shared publications Fernanda Maria Borghi
Affiliation Universidade Estadual de Maringá, Maringá, Brazil
2 shared publicationsGustavo Gomes Resende
Affiliation Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications
Latest Publications
- Open Access
- 29 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0273789
Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study
Introduction: Rheumatoid arthritis (RA) composite disease activity indices have become handy tools in daily clinical practice and crucial in defining remission or low disease activity, the main target of the RA treatment. However, there is no definition of the best index to assess disease activity in clinical practice. Objectives: To compare the residual activity among the indices with the ACR/EULAR remission criteria (Boolean method) to identify the most feasible for assessing remission in daily practice, also considering correlation and concordance, sensibility, and specificity. Patients and methods: We selected 1116 patients with established RA from the real-life rheumatoid arthritis study database—REAL. The composite disease activity indices—DAS28-ESR, DAS28-CRP, SDAI, and CDAI–and their components were compared to the Boolean method to identify residual activity using binomial regression. The indices were analyzed for correlation and agreement using the Spearman index and weighted kappa. The chi-square test evaluated sensibility and specificity for remission based on the Boolean method. Results: DAS28-CRP overestimated remission and confirmed higher residual activity than SDAI and CDAI. The indices showed good correlation and agreement, with a better relationship between SDAI and CDAI (k:0,88). CDAI and SDAI showed higher sensitivity and specificity for remission based on the Boolean method. CDAI was performed in 99% of patients, while DAS28 and SDAI were completed in approximately 85%. Conclusions: Although all composite indices of activity can be used in clinical practice and showed good agreement, CDAI and SDAI have better performance in evaluating remission based on the Boolean method, showing less residual activity and higher sensibility and specificity. In addition, CDAI seems to be more feasible for disease activity evaluation in daily clinical practice, especially in developing countries.
- 29 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0273789
Open AccessComparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study
Introduction: Rheumatoid arthritis (RA) composite disease activity indices have become handy tools in daily clinical practice and crucial in defining remission or low disease activity, the main target of the RA treatment. However, there is no definition of the best index to assess disease activity in clinical practice. Objectives: To compare the residual activity among the indices with the ACR/EULAR remission criteria (Boolean method) to identify the most feasible for assessing remission in daily practice, also considering correlation and concordance, sensibility, and specificity. Patients and methods: We selected 1116 patients with established RA from the real-life rheumatoid arthritis study database—REAL. The composite disease activity indices—DAS28-ESR, DAS28-CRP, SDAI, and CDAI–and their components were compared to the Boolean method to identify residual activity using binomial regression. The indices were analyzed for correlation and agreement using the Spearman index and weighted kappa. The chi-square test evaluated sensibility and specificity for remission based on the Boolean method. Results: DAS28-CRP overestimated remission and confirmed higher residual activity than SDAI and CDAI. The indices showed good correlation and agreement, with a better relationship between SDAI and CDAI (k:0,88). CDAI and SDAI showed higher sensitivity and specificity for remission based on the Boolean method. CDAI was performed in 99% of patients, while DAS28 and SDAI were completed in approximately 85%. Conclusions: Although all composite indices of activity can be used in clinical practice and showed good agreement, CDAI and SDAI have better performance in evaluating remission based on the Boolean method, showing less residual activity and higher sensibility and specificity. In addition, CDAI seems to be more feasible for disease activity evaluation in daily clinical practice, especially in developing countries.
- Open Access
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
JAK INHIBITORS VS BIOLOGICS FOR RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS FROM AN ONGOING OBSERVATIONAL REAL-WORLD PROSPECTIVE COHORT
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
Open AccessJAK INHIBITORS VS BIOLOGICS FOR RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS FROM AN ONGOING OBSERVATIONAL REAL-WORLD PROSPECTIVE COHORT
- Open Access
- 29 December 2021
- Published by Editora Unijui in Revista Contexto & Saúde
- Vol. 21 (44) , 375-384
COMORBIDADES ENTRE PACIENTES COM ARTRITE REUMATOIDE E SUA ASSOCIAÇÃO COM A DESCOMPENSAÇÃO CLÍNICA
A artrite reumatoide (AR) é uma doença inflamatória crônica que acomete as articulações e evolui com incapacidade funcional. Pacientes com AR, frequentemente, apresentam comorbidades que podem influenciar a evolução clínica da doença. Objetivo: avaliar a associação entre comorbidades e o perfil de atividade da AR entre pacientes em acompanhamento ambulatorial em um hospital universitário público. Métodos: trata-se de um estudo transversal, que coletou coletados dados demográficos, de doenças, sobre hábitos de vida e perfil da AR, de uma amostra representativa de pacientes diagnosticados com AR deste ambulatório. Realizou-se uma análise descritiva e análises uni e multivariada para avaliar fatores associados com a variável dependente DAS28 (Disease Activity Score 28). Resultados: Duzentos e um pacientes foram incluídos, destes 172 (85,6%) eram mulheres, e a média de idade foi de 60,3 ± 11,5. Sete pacientes (3.5%) eram obesos, 17 (8.5%) tabagistas, 106 (52,7%) hipertensos, 38 (18,9%) diabéticos e 72 (35,8%) apresentavam dislipidemias. Foi identificado na amostra um índice de comorbidade funcional médio de 2,3 ± 1,19, e uma média de 4,2 ± 2,2 doenças por paciente. Idade maior ou igual a 60 anos (OR=0,40; IC95% 0,21-0,74) e ser diabético (OR=2,96; IC95% 1,30-6,74) mostraram-se associadas com o DAS28 moderado/alto. Conclusão: a presença de comorbidades se mostrou frequente na população estudada, e idade igual ou superior a 60 anos mostrou-se associado negativamente, enquanto o diagnóstico de diabetes mellitus (DM) associado positivamente à atividade da doença moderada à alta. Os achados reforçam a necessidade de monitorização da DM entre esses pacientes, especialmente os mais jovens.
- 29 December 2021
- Published by Editora Unijui in Revista Contexto & Saúde
- Vol. 21 (44) , 375-384
Open AccessCOMORBIDADES ENTRE PACIENTES COM ARTRITE REUMATOIDE E SUA ASSOCIAÇÃO COM A DESCOMPENSAÇÃO CLÍNICA
A artrite reumatoide (AR) é uma doença inflamatória crônica que acomete as articulações e evolui com incapacidade funcional. Pacientes com AR, frequentemente, apresentam comorbidades que podem influenciar a evolução clínica da doença. Objetivo: avaliar a associação entre comorbidades e o perfil de atividade da AR entre pacientes em acompanhamento ambulatorial em um hospital universitário público. Métodos: trata-se de um estudo transversal, que coletou coletados dados demográficos, de doenças, sobre hábitos de vida e perfil da AR, de uma amostra representativa de pacientes diagnosticados com AR deste ambulatório. Realizou-se uma análise descritiva e análises uni e multivariada para avaliar fatores associados com a variável dependente DAS28 (Disease Activity Score 28). Resultados: Duzentos e um pacientes foram incluídos, destes 172 (85,6%) eram mulheres, e a média de idade foi de 60,3 ± 11,5. Sete pacientes (3.5%) eram obesos, 17 (8.5%) tabagistas, 106 (52,7%) hipertensos, 38 (18,9%) diabéticos e 72 (35,8%) apresentavam dislipidemias. Foi identificado na amostra um índice de comorbidade funcional médio de 2,3 ± 1,19, e uma média de 4,2 ± 2,2 doenças por paciente. Idade maior ou igual a 60 anos (OR=0,40; IC95% 0,21-0,74) e ser diabético (OR=2,96; IC95% 1,30-6,74) mostraram-se associadas com o DAS28 moderado/alto. Conclusão: a presença de comorbidades se mostrou frequente na população estudada, e idade igual ou superior a 60 anos mostrou-se associado negativamente, enquanto o diagnóstico de diabetes mellitus (DM) associado positivamente à atividade da doença moderada à alta. Os achados reforçam a necessidade de monitorização da DM entre esses pacientes, especialmente os mais jovens.
- 1 April 2021
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 40 (2) , 100811
Quadratus Lumborum block for acute visceral pain
- 1 April 2021
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 40 (2) , 100811
Quadratus Lumborum block for acute visceral pain
- Open Access
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
ONLINE RELEASE OF AN EDUCATIONAL BOOKLET ADDRESSING SCLERODERMIC HANDS CARE
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
Open AccessONLINE RELEASE OF AN EDUCATIONAL BOOKLET ADDRESSING SCLERODERMIC HANDS CARE
- Open Access
- 3 April 2019
- Published by Springer Nature in Advances in Rheumatology
- Vol. 59 (1) , 15
Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis
- 3 April 2019
- Published by Springer Nature in Advances in Rheumatology
- Vol. 59 (1) , 15
Open AccessMethotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis
- Open Access
- 1 March 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (3) , e0213219
Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort
The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.
- 1 March 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (3) , e0213219
Open AccessCauses of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort
The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.
- 11 June 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (9) , 1671-1677
Leptin as an obesity marker in rheumatoid arthritis
The determination of excess of body fat mass provides a more suitable determinant of obesity in rheumatoid arthritis patients; however, body mass index (BMI) may not be accurate for the quantification of adiposity. To identify a marker of excess adiposity in women with rheumatoid arthritis (RA) using different methods for fat mass evaluation. A cross-sectional study was conducted in adult female patients with RA. Disease activity was assessed by DAS28-ESR, and obesity was determined by waist circumference (WC), BMI and dual-energy X-ray absorptiometry (DXA). The Human Bone Metabolism kit (Merck Millipore, Darmstadt, Alemanha) was used to determine the plasma levels of leptin, TNF-α, IL-6, and IL-1β by quantification of serum proteins by technical microspheres (LUMINEX, TX, USA). Adiponectin was measured by enzyme-linked immunosorbent assay sandwich kit (R&D Systems, Minneapolis, MN, USA). Eighty-nine female patients, median age of 55.4 (± 11.6) years, and median disease duration of 16.4 (± 14.9) years were included. The frequency of obesity was 33.7% according to BMI, 89.9% with WC, and 56.1% with DXA. The median serum leptin concentration was the only marker that correlated with body fat percentage according to the three methods. This correlation was positive and not influenced by DAS28, C-reactive protein, erythrocyte sedimentation rate, or inflammatory cytokines levels (IL-6, TNF-α, IL-1β). Analysis of ROC curves determined the cut-off point of 10.3 ng/mL of leptin as an obesity marker, with a sensitivity of 96.43% and a specificity of 23.81%. Serum leptin correlates positively with fat mass and is potentially useful in excess fat mass determination in clinical practice.
- 11 June 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (9) , 1671-1677
Leptin as an obesity marker in rheumatoid arthritis
The determination of excess of body fat mass provides a more suitable determinant of obesity in rheumatoid arthritis patients; however, body mass index (BMI) may not be accurate for the quantification of adiposity. To identify a marker of excess adiposity in women with rheumatoid arthritis (RA) using different methods for fat mass evaluation. A cross-sectional study was conducted in adult female patients with RA. Disease activity was assessed by DAS28-ESR, and obesity was determined by waist circumference (WC), BMI and dual-energy X-ray absorptiometry (DXA). The Human Bone Metabolism kit (Merck Millipore, Darmstadt, Alemanha) was used to determine the plasma levels of leptin, TNF-α, IL-6, and IL-1β by quantification of serum proteins by technical microspheres (LUMINEX, TX, USA). Adiponectin was measured by enzyme-linked immunosorbent assay sandwich kit (R&D Systems, Minneapolis, MN, USA). Eighty-nine female patients, median age of 55.4 (± 11.6) years, and median disease duration of 16.4 (± 14.9) years were included. The frequency of obesity was 33.7% according to BMI, 89.9% with WC, and 56.1% with DXA. The median serum leptin concentration was the only marker that correlated with body fat percentage according to the three methods. This correlation was positive and not influenced by DAS28, C-reactive protein, erythrocyte sedimentation rate, or inflammatory cytokines levels (IL-6, TNF-α, IL-1β). Analysis of ROC curves determined the cut-off point of 10.3 ng/mL of leptin as an obesity marker, with a sensitivity of 96.43% and a specificity of 23.81%. Serum leptin correlates positively with fat mass and is potentially useful in excess fat mass determination in clinical practice.